Anktiva is an exciting new cancer immunotherapy that helps the immune system fight and kill cancer cells. Doctors believe it could support treatment for many cancers when used in the right personalized combinations — but what is it really, and why won’t it work the same way for every patient?

In this episode of Outsmart Cancer, Dr. Dino Prato breaks down the science, the hype, and the clinical reality behind Anktiva, an FDA-approved IL-15 super agonist cytokine currently indicated for invasive bladder cancer.

Unlike many targeted cancer drugs that only slow disease, Anktiva is designed to activate the immune system — particularly natural killer cells and CD8 T cells — with the goal of cytotoxic tumor kill. But immune stimulation alone is not enough.

Dr. Prato explains why immunotherapies like Anktiva require the right tumor information to be effective. Without exposing tumor antigens, neoantigens, and damage-associated molecular patterns (DAMPs), even powerful immune activators may produce only short-term responses.

This episode explores how precision oncology integrates deep DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology to identify the right patients, pathways, and combinations. Dr. Prato outlines how direct-to-tumor strategies, micro-dosing, off-label use, and immune-supportive phytotherapeutics can transform Anktiva from a single drug into part of a coordinated immune attack.

🎯 What You’ll Learn in This Episode:
- What Anktiva is and how IL-15 immunotherapy works
- Why immune stimulation alone doesn’t guarantee success
- The role of NK cells, CD8 T cells, and immune memory
- Why tumor information must be released for immunotherapy to work
- How precision testing guides on- and off-label use
- Why plasma exchange may be necessary during strong immune responses
- How combination strategies outperform single-agent therapy

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493